{"id":"tyroserleutide-for-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the release of insulin from the pancreas in response to elevated blood glucose levels, thereby lowering blood glucose levels. This action is glucose-dependent, meaning that insulin secretion is only stimulated when blood glucose levels are high, reducing the risk of hypoglycemia.","oneSentence":"Tyroserleutide for injection is a recombinant human proinsulin-derived peptide that mimics the action of incretin hormones to enhance glucose-dependent insulin secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:53.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03516448","phase":"PHASE3","title":"Expanding Phase III Study of Tyroserleutide for Injection","status":"UNKNOWN","sponsor":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","startDate":"2016-03-24","conditions":"Hepatocellular Carcinoma","enrollment":352},{"nctId":"NCT01489566","phase":"PHASE3","title":"Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients","status":"UNKNOWN","sponsor":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","startDate":"2011-07","conditions":"Hepatocellular,Carcinoma","enrollment":300},{"nctId":"NCT00644020","phase":"","title":"Phase ⅡStudy of Tyroserleutide for Injection in Hepatocellular Carcinoma(HCC) Patients","status":"UNKNOWN","sponsor":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","startDate":"2007-12","conditions":"Hepatocellular Carcinoma","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tyroserleutide for injection","genericName":"Tyroserleutide for injection","companyName":"Shenzhen Kangzhe Pharmaceutical Co., Ltd.","companyId":"shenzhen-kangzhe-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tyroserleutide for injection is being studied in a Phase III clinical trial for the treatment of Hepatocellular Carcinoma. The exact mechanism of action of Tyroserleutide is currently unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}